HeartSciences (HSCS) Q4 2025 earnings summary

Executive summary

• Achieved major strategic progress in fiscal 2025, focusing on AI and cloud-based ECG technologies for broader healthcare deployment.

• Launched MyoVista Insights, a cloud-native ECG management platform, with phased rollout starting May 2025.

• Nearing FDA 510(k) submission for MyoVista wavECG device, aligning with updated clinical guidelines.

• Received FDA Breakthrough Device designation for aortic stenosis ECG algorithm.

• CMS approved reimbursement for AI-ECG algorithms at $128 per test in 2025.

Financial highlights

• Reported no meaningful revenue for fiscal year 2025.

• Held $1.1 million in cash and cash equivalents and $0.2 million in shareholders' equity as of April 30, 2025.

• Raised $3.1 million in gross proceeds post year-end via Reg A+ offering.

• Converted $0.9 million of debt into equity after fiscal year-end.

Outlook and guidance

• Targeting commercialization and revenue generation in calendar 2026, pending regulatory clearances.

• Plans FDA submission for first cloud-based algorithm for reduced ejection fraction in H1 2026, with potential clearance later that year.